It is at a very early stage, which says it is to do primarily with primary TMAU (the genetic form), which hopefully means it can improve FMO3 function if it is deficient in some way. Or it may be to with reducing the absorption of trimethylamine into the bloodstream, which would be good but not as good as improvement of FMO3 function.
Link :
Therapy for the body and breath malodour disorder Trimethylaminuria (TMAU)
Lead Research Organisation: University College London
Department Name: Structural Molecular Biology
The paper says "This industry would benefit from development of the therapeutic for clinic and subsequent sales of the product - this would be within 2 to 5 years of the pre-clinical study end"
It also says
"We have established very promising early proof of concept data in a rodent model indicating that this therapeutic approach is both realistic and potentially of great use to humans suffering from this condition. "
So it is very exciting news for those who feel trimethylaminuria totally explains their metabolic malodor, but would be in my opinion possibly a 'cure' for what I term 'FMO3 substrate malodor syndrome' and what I think most 'metabolic' malodor cases have, if it improves FMO3 function in some way.
The paper ends by saying
"Researchers interested in the approach we have selected to develop the therapy, will benefit from our findings and be able to use our knowledge in future projects that target metabolic disorders. Anticipated publication of results is during and within one year of the project end. "
0 comments:
Post a Comment